Tags

Type your tag names separated by a space and hit enter

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
J Clin Oncol. 2009 Sep 20; 27(27):4548-54.JC

Abstract

PURPOSE

The HD9 trial of the German Hodgkin Study Group compared two different doses (baseline and escalated) of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) chemotherapy regimen in 1,196 patients with advanced-stage Hodgkin's lymphoma (HL). The previous analysis with 5 years median follow-up had indicated improved tumor control with BEACOPP escalated. Since the long-term safety and efficacy of this regimen has been debated, we report the 10-year follow-up.

PATIENTS AND METHODS

Patients received one of three chemotherapy regimens: eight cycles of cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) alternating with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD); eight cycles of BEACOPP baseline; or eight cycles of BEACOPP escalated.

RESULTS

Median follow-up was 111 months. At 10 years, freedom from treatment failure (FFTF) was 64%, 70%, and 82% with OS rates of 75%, 80%, and 86% for patients treated with COPP/ABVD (arm A), BEACOPP baseline (arm B), and BEACOPP escalated (arm C), respectively (P < .001). BEACOPP escalated was significantly better than BEACOPP baseline in terms of FFTF (P < .0001) and OS (P = .0053). A total of 74 second malignancies (6.2%) were documented, including acute myeloid leukemia (0.4%, 1.5%, and 3.0%), non-Hodgkin's lymphoma (2.7%, 1.7%, and 1.0%), and solid tumors (2.7%, 3.4%, and 1.9%). The corresponding overall secondary malignancy rates were 5.7%, 6.6%, and 6.0%, respectively.

CONCLUSION

The 10-year follow-up of the HD9 trial demonstrates a stabilized significant improvement in long-term FFTF and OS for BEACOPP escalated in advanced-stage HL. These results challenge ABVD as standard of care for this patient population.

Authors+Show Affiliations

Klinik I für Innere Medizin, Universitätsklinik Köln, Kerpener Strasse 62, 50931 Köln, Germany. a.engert@uni-koeln.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

19704068

Citation

Engert, Andreas, et al. "Escalated-dose BEACOPP in the Treatment of Patients With Advanced-stage Hodgkin's Lymphoma: 10 Years of Follow-up of the GHSG HD9 Study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 27, no. 27, 2009, pp. 4548-54.
Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548-54.
Engert, A., Diehl, V., Franklin, J., Lohri, A., Dörken, B., Ludwig, W. D., Koch, P., Hänel, M., Pfreundschuh, M., Wilhelm, M., Trümper, L., Aulitzky, W. E., Bentz, M., Rummel, M., Sezer, O., Müller-Hermelink, H. K., Hasenclever, D., & Löffler, M. (2009). Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 27(27), 4548-54. https://doi.org/10.1200/JCO.2008.19.8820
Engert A, et al. Escalated-dose BEACOPP in the Treatment of Patients With Advanced-stage Hodgkin's Lymphoma: 10 Years of Follow-up of the GHSG HD9 Study. J Clin Oncol. 2009 Sep 20;27(27):4548-54. PubMed PMID: 19704068.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. AU - Engert,Andreas, AU - Diehl,Volker, AU - Franklin,Jeremy, AU - Lohri,Andreas, AU - Dörken,Bernd, AU - Ludwig,Wolf-Dieter, AU - Koch,Peter, AU - Hänel,Mathias, AU - Pfreundschuh,Michael, AU - Wilhelm,Martin, AU - Trümper,Lorenz, AU - Aulitzky,Walter-Erich, AU - Bentz,Martin, AU - Rummel,Mathias, AU - Sezer,Orhan, AU - Müller-Hermelink,Hans-Konrad, AU - Hasenclever,Dirk, AU - Löffler,Markus, Y1 - 2009/08/24/ PY - 2009/8/26/entrez PY - 2009/8/26/pubmed PY - 2009/11/5/medline SP - 4548 EP - 54 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J. Clin. Oncol. VL - 27 IS - 27 N2 - PURPOSE: The HD9 trial of the German Hodgkin Study Group compared two different doses (baseline and escalated) of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) chemotherapy regimen in 1,196 patients with advanced-stage Hodgkin's lymphoma (HL). The previous analysis with 5 years median follow-up had indicated improved tumor control with BEACOPP escalated. Since the long-term safety and efficacy of this regimen has been debated, we report the 10-year follow-up. PATIENTS AND METHODS: Patients received one of three chemotherapy regimens: eight cycles of cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) alternating with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD); eight cycles of BEACOPP baseline; or eight cycles of BEACOPP escalated. RESULTS: Median follow-up was 111 months. At 10 years, freedom from treatment failure (FFTF) was 64%, 70%, and 82% with OS rates of 75%, 80%, and 86% for patients treated with COPP/ABVD (arm A), BEACOPP baseline (arm B), and BEACOPP escalated (arm C), respectively (P < .001). BEACOPP escalated was significantly better than BEACOPP baseline in terms of FFTF (P < .0001) and OS (P = .0053). A total of 74 second malignancies (6.2%) were documented, including acute myeloid leukemia (0.4%, 1.5%, and 3.0%), non-Hodgkin's lymphoma (2.7%, 1.7%, and 1.0%), and solid tumors (2.7%, 3.4%, and 1.9%). The corresponding overall secondary malignancy rates were 5.7%, 6.6%, and 6.0%, respectively. CONCLUSION: The 10-year follow-up of the HD9 trial demonstrates a stabilized significant improvement in long-term FFTF and OS for BEACOPP escalated in advanced-stage HL. These results challenge ABVD as standard of care for this patient population. SN - 1527-7755 UR - https://www.unboundmedicine.com/medline/citation/19704068/Escalated_dose_BEACOPP_in_the_treatment_of_patients_with_advanced_stage_Hodgkin's_lymphoma:_10_years_of_follow_up_of_the_GHSG_HD9_study_ L2 - http://ascopubs.org/doi/full/10.1200/JCO.2008.19.8820?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -